Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, talks on targeted therapies that are being developed for chronic lymphocytic leukemia (CLL), specifically discussing venetoclax, obinutuzumab and ibrutinib combinations as well as the addition of zanabrutinib This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).